TY - JOUR
TI - The impact of preimplantation genetic testing for aneuploidies (PGT-A) on clinical outcomes in high risk patients
AU - Pantou, A.
AU - Mitrakos, A.
AU - Kokkali, G.
AU - Petroutsou, K.
AU - Tounta, G.
AU - Lazaros, L.
AU - Dimopoulos, A.
AU - Sfakianoudis, K.
AU - Pantos, K.
AU - Koutsilieris, M.
AU - Mavrou, A.
AU - Kanavakis, E.
AU - Tzetis, M.
JO - Journal of Assisted Reproduction and Genetics
PY - 2022
VL - 39
TODO - 6
SP - 1341-1349
PB - Springer-Verlag
SN - 1058-0468, 1573-7330
TODO - 10.1007/s10815-022-02461-9
TODO - null
TODO - Purpose: To investigate whether preimplantation genetic testing for aneuploidy (PGT-A) improves the clinical outcome in patients with advanced maternal age (AMA), recurrent miscarriages (RM), and recurrent implantation failure (RIF). Methods: Retrospective cohort study from a single IVF center and a single genetics laboratory. One hundred seventy-six patients undergoing PGT-A were assigned to three groups: an AMA group, an RM group, and a RIF group. Two hundred seventy-nine patients that did not undergo PGT-A were used as controls and subgrouped similarly to the PGT-A cohort. For the PGT-A groups, trophectoderm biopsy was performed and array comparative genomic hybridization was used for PGT-A. Clinical outcomes were compared with the control groups. Results: In the RM group, we observed a significant decrease of early pregnancy loss rates in the PGT-A group (18.1% vs 75%) and a significant increase in live birth rate per transfer (50% vs 12.5%) and live birth rate per patient (36% vs 12.5%). In the RIF group, a statistically significant increase in the implantation rate per transfer (69.5% vs 33.3%) as well as the live birth rate per embryo transfer (47.8% vs 19%) was observed. In the AMA group, a statistically significant reduction in biochemical pregnancy loss was observed (3.7% vs 31.5%); however, live birth rates per embryo transfer and per patient were not significantly higher than the control group. Conclusion: Our results agree with recently published studies, which suggest caution in the universal application of PGT-A in women with infertility. Instead, a more personalized approach by choosing the right candidates for PGT-A intervention should be followed. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
ER -